Shan Liao
PhD School of Medicine Yale University
Areas of Research
Lymphedema impacts an estimated 140 million people worldwide. Lymphedema is a condition of uncontrolled fluid accumulation and tissue swelling. Lymphedema can cause discomfort, immobility and organ dysfunction. Edematous tissue in lymphedema is under high risk of infection. Primary lymphedema is caused by genetic defects and is relatively rare. The major cause of lymphedema in the world is lymphatic filariasis, which affects an estimated 140 million people. Another important cause of lymphedema is the damage to the lymphatic vessels and LNs associated with cancer and cancer therapies, which impact almost all of the cancer types that involve cancer spread via the lymphatic vessels. For instance, between 38 and 89% of breast cancer patients will eventually develop Lymphedema impacts an estimated 140 million people worldwide. Lymphedema is a condition of uncontrolled fluid accumulation and tissue swelling. Lymphedema can cause discomfort, immobility and organ dysfunction. Edematous tissue in lymphedema is under high risk of infection. Primary lymphedema is caused by genetic defects and is relatively rare. The major cause of lymphedema in the world is lymphatic filariasis. Another important cause of lymphedema is the damage to the lymphatic vessels and LNs associated with cancer and cancer therapies, which impact almost all of the cancer types that involve cancer spread via the lymphatic vessels. Some lymphedema patients exhibit significant body disfigurement and need life long intervention with pressure garments, which cause a huge psycho-social and economic impact on these patients. Currently, there is no cure for lymphedema. Lack of knowledge regarding the regulation of lymph flow has been the barrier for the disease prevention or treatment. Lymphatic vessels maintain fluid balance and transport tissue waste, pathogens and cells to lymph nodes for protection by the immune system. In the lymph node, lymph flow direction determines the time, the location and the cell types that encounter the antigens after an immune stimulation. Our study aims to understand how lymph flow is regulated in healthy and diseased states. We will determine how altered lymph flow affects host immunity in inflammation and cancer. Our work aims to target lymph flow in order to develop potential therapeutic methods to reduce edema, improve host immune protection or anti-tumor immunity.
More information
http://www.ucalgary.ca/irn/faculty/shanliaoWorking with this supervisor
PhD student candidates should have a BS or MS in Molecular Biology, Immunology, Cancer or a related discipline, a strong academic background, good English skills and an enthusiasm for research.
Contact this supervisor
Complete the following form if you are interested in working with this supervisor for your Graduate Program. All fields are required, unless indicated otherwise.
UCalgary Notice of Collection
The University of Calgary (UCalgary) respects your privacy and is
committed to ensuring the privacy of all students, staff, and community members. Your personal information is being
collected under the authority of section 4(c) of the Protection of Privacy Act (POPA). It will be collected, used
and disclosed for the purposes outlined in UCalgary’s
Notice of
Collection, Use and Disclosure of Personal Information and managed in accordance with UCalgary’s
Privacy
Management Program.
Your personal information may be input into automated systems to generate content or make decisions,
recommendations, or predictions. If you have questions regarding this notice or UCalgary’s collection,
use, or disclosure of your personal information, please contact
accessandprivacy@ucalgary.ca.